Abstract: The present invention relates to the use of alkali hydroxide for the regeneration of apheresis columns for the affinity chromatographic removal of CRP and a method for the simplified regeneration of apheresis columns for the affinity chromatographic removal of CRP with the use of an alkali hydroxide solution and apheresis devices which are designed in such a manner as to be resistant to alkali hydroxide solutions and to allow the regeneration of apheresis columns for the affinity chromatographic removal of CRP in continuous operation.

Abstract: The present invention relates to an apheresis device (1) for the extracorporeal removal of C-reactive protein from blood of a patient, wherein the apheresis device is connectable to the blood circulation of the patient. The blood is pumped via a part of the extracorporeal circulation system (2) of the apheresis device (1) according to the invention to a cell separator (7) for separation of the blood into blood plasma and cellular components. Via a first outlet of the cell separator (7), the separated blood plasma is directed by means of a plasma line (8A) to an apheresis column (4) for affinity chromatographic removal of C-reactive protein from the blood plasma. After removal of the C-reactive protein from the blood plasma of the patient, said now treated blood plasma is combined with the cellular components of the blood via a plasma line (8B).

Abstract: This disclosure relates generally to storage device, and more particularly to method and system for dynamically allocating front end ports in a storage device. In one embodiment, the method may include determining a need for re-allocating a set of servers being served by a first set of front end ports from among a plurality of front end ports of the storage device, evaluating remaining ports of the plurality of front end ports to identify a second set of front end ports to serve the set of servers, dynamically updating a configuration of each of the plurality of front end ports by emulating virtual worldwide names (vWWNs) of the first set of front end ports onto the second set of front end ports, and serving the set of servers from the second set of front-end ports based on the updated configuration.

Abstract: This disclosure relates generally to storage device, and more particularly to method and system for dynamically allocating front end ports in a storage device. In one embodiment, the method may include determining a need for re-allocating a set of servers being served by a first set of front end ports from among a plurality of front end ports of the storage device, evaluating remaining ports of the plurality of front end ports to identify a second set of front end ports to serve the set of servers, dynamically updating a configuration of each of the plurality of front end ports by emulating virtual worldwide names (vWWNs) of the first set of front end ports onto the second set of front end ports, and serving the set of servers from the second set of front-end ports based on the updated configuration.

Abstract: The present invention provides phosphoryl choline derivatives of general formula (I), which are suitable to be immobilized on a solid support to provide a separation material of general formula (II), which bind with both high affinity and high specificity to a protein, more specifically to C-reactive protein and anti-phosphoryl choline antibodies. Said separation materials are particularly useful in the extracorporeal removal of C-reactive protein and anti-phosphoryl choline antibodies from a biological fluid of a patient for prophylaxis and/or treatment of immune dysfunctions and cardiovascular diseases. Also provided is a column that comprises the separation material of general formula (II), as well as a device containing the column. Formula (I), wherein variable X is selected from: —SH, —NHR3, —C?CH, —CH?CH2, —N3 and —CHO; the other variables are as defined in the claims: Formula (II), wherein variable “A” represents a solid support. “A” as well as the other variables are defined in detail in the claims.

Abstract: The invention relates to the use of a citrate solution for affinity-chromatographic removal of C-reactive protein (CRP) from biological fluids, wherein the CRP is affinity-chromatographically removed using (Ca2+-dependent) binding of CRP to a column material functionalized with ?-phosphonooxyalkyl ammonium groups and/or with ?-ammoniumalkoxy-hydroxy-phosphoryloxy groups.

Abstract: The invention relates to the use of a citrate solution for affinity-chromatographic removal of C-reactive protein (CRP) from biological fluids, wherein the CRP is affinity-chromatographically removed using (Ca2+-dependent) binding of CRP to a column material functionalized with ?-phosphonooxyalkyl ammonium groups and/or with ?-ammoniumalkoxy-hydroxy-phosphoryloxy groups.

Abstract: The present invention provides phosphoryl choline derivatives of general formula (I), which are suitable to be immobilized on a solid support to provide a separation material of general formula (II), which bind with both high affinity and high specificity to a protein, more specifically to C-reactive protein and anti-phosphoryl choline antibodies. Said separation materials are particularly useful in the extracorporeal removal of C-reactive protein and anti-phosphoryl choline antibodies from a biological fluid of a patient for prophylaxis and/or treatment of immune dysfunctions and cardiovascular diseases. Also provided is a column that comprises the separation material of general formula (II), as well as a device containing the column. Formula (I), wherein variable X is selected from: —SH, —NHR3, —C?CH, —CH?CH2, —N3and —CHO; the other variables are as defined in the claims: Formula (II), wherein variable “A” represents a solid support. “A” as well as the other variables are defined in detail in the claims.

Abstract: Use of a compound comprising at least a structural entity which binds or is an antagonist for interleukin-6 (IL-6) and/or the IL-6 receptor or parts of it, preferably human IL-6 which compound depletes IL-6 from a solution or blocks at least one or more IL-6 functions on cell surfaces or in a solution for manufacturing of a medicament for the treatment or prevention of diseases selected from the group consisting of endothelial injury, destruction, increased risk for endothelial injury or destruction or immune disorders other than rheumatoid arthritis and combinations thereof.

Abstract: A compound comprising at least a structural entity which binds secretory phospholipase A2 IIA (sPLA2 IIA) or parts of it and more preferably human sPLA2 IIA and which a.) blocks at least one or more sPLA2 IIA function on cell surfaces or in a solution, preferably blood or other body fluids or from tissues, most preferably in vivo, b.) and/or depletes sPLA2 IIA from a solution, preferably blood or other body fluids or from tissues, most preferably in vivo.

Abstract: An isolated protein having at least 90% homology with the dimeric protein having the following amino acid sequence with the proviso that at the C-terminal end of the monomeric forms, 2 to 10 amino acid distance from Z2, a Cys is present for forming the dimeric or multimeric protein, Z1 is a signal peptide for protein transport to the ER and/or through the plasma membrane or NH2 or a derivative of an NH2 group such as an alkylated, or acylated derivative, or polyethylene glycol (PEG) moiety, Z2 is an amino acid residue with up to 20, in particular 10 or 8 amino acids which are selected of substantially non-hydrophobic naturally occurring amino acids or COOZ3 wherein Z3 is hydrogen, a metal ion, a hydrocarbon moiety substituted or non-substituted with heteroatoms.

Abstract: An isolated protein having at least 90% homology with the dimeric protein having the following amino acid sequence with the proviso that at the C-terminal end of the monomeric forms, 2 to 10 amino acid distance from Z2, a Cys is present for forming the dimeric or multimeric protein, Z1 is a signal peptide for protein transport to the ER and/or through the plasma membrane or NH2 or a derivative of an NH2 group such as an alkylated, or acylated derivative, or polyethylene glycol (PEG) moiety, Z2 is an amino acid residue with up to 20, in particular 10 or 8 amino acids which are selected of substantially non-hydrophobic naturally occurring amino acids or COOZ3 wherein Z3 is hydrogen, a metal ion, a hydrocarbon moiety substituted or non-substituted with heteroatoms.

Abstract: A compound comprising at least a structural entity which binds C-reactive protein (CRP) or parts of it or CRP in its monomeric, pentameric or multimeric form, preferably human CRP and which a.) blocks one or more CRP functions on cell surfaces or in a solution, preferably blood or other body fluids or from tissues, most preferably in vivo, b.) and/or depletes CRP from a solution, preferably blood or other body fluids or from tissues, most preferably in vivo.

Abstract: Use of a compound comprising at least a structural entity which binds or is an antagonist for interleukin-6 (IL-6) and/or the IL-6 receptor or parts of it, preferably human IL-6 which compound depletes IL-6 from a solution or blocks at least one or more IL-6 functions on cell surfaces or in a solution for manufacturing of a medicament for the treatment or prevention of diseases selected from the group consisting of endothelial injury, destruction, increased risk for endothelial injury or destruction or immune disorders other than rheumatoid arthritis and combinations thereof.

Abstract: An isolated protein having at least 90% homology with the dimeric protein having the following amino acid sequence (I) with the proviso that at the C-terminal end of the monomeric forms, 2 to 10 amino acid distance from Z2, a Cys is present for forming the dimeric or multimeric protein, Z1 is a signal peptide for protein transport to the ER and/or through the plasma membrane or NH2 or a derivative of an NH2 group such as an alkylated, or acylated derivative, or polyethylene glycol (PEG) moiety, Z2 is an amino acid residue with up to 20, in particular 10 or 8 amino acids which are selected of substantially non-hydrophobic naturally occurring amino acids or COOZ3 wherein Z3 is hydrogen, a metal ion, a hydrocarbon moiety substituted or non-substituted with heteroatoms.

Abstract: A compound comprising at least a structural entity which binds secretory phospholipase A2 IIA (sPLA2 IIA) or parts of it and more preferably human sPLA2 IIA and which a.) blocks at least one or more sPLA2 IIA function on cell surfaces or in a solution, preferably blood or other body fluids or from tissues, most preferably in vivo, b.) and/or depletes sPLA2 IIA from a solution, preferably blood or other body fluids or from tissues, most preferably in vivo.

Abstract: A compound comprising at least a structural entity which binds C-reactive protein (CRP) or parts of it or CRP in its monomeric, pentameric or multimeric form, preferably human CRP and which a) blocks one or more CRP functions on cell surfaces or in a solution, preferably blood or other body fluids or from tissues, most preferably in vivo, b.) and/or depletes CRP from a solution, preferably blood or other body fluids or from tissues, most preferably in vivo.

Abstract: The present invention relates to the identification of molecules, which are specific to CD80 and CD86 antigens. Also preferably, such antibodies are capable of inhibiting the binding of CD28 and CTLA4 to those receptors. Those molecules are able to inhibit T cell mediated immune reactions.

Abstract: A compound comprising at least a structural entity which binds secretory phospholipase A2 IIA (sPLA2 IIA) or parts of it and more preferably human sPLA2 IIA and which a.) blocks at least one or more sPLA2 IIA function on cell surfaces or in a solution, preferably blood or other body fluids or from tissues, most preferably in vivo, b.) and/or depletes sPLA2 IIA from a solution, preferably blood or other body fluids or from tissues, most preferably in vivo.

Abstract: Use of a compound comprising at least a structural entity which binds or is an antagonist for interleukin-6 (IL-6) and/or the IL-6 receptor or parts of it, preferably human IL-6 which compound depletes IL-6 from a solution or blocks at least one or more IL-6 functions on cell surfaces or in a solution for manufacturing of a medicament for the treatment or prevention of diseases selected from the group consisting of endothelial injury, destruction, increased risk for endothelial injury or destruction or immune disorders other than rheumatoid arthritis and combinations thereof.